title: Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.
authors.affiliation: Department of Gynecologic Oncology, University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030, USA. asood@mdanderson.org
authors.forename: Anil K
authors.initials: AK
authors.lastname: Sood
authors.forename: Richard
authors.initials: R
authors.lastname: Lush
authors.forename: John P
authors.initials: JP
authors.lastname: Geisler
authors.forename: Mark S
authors.initials: MS
authors.lastname: Shahin
authors.forename: Linda
authors.initials: L
authors.lastname: Sanders
authors.forename: Dan
authors.initials: D
authors.lastname: Sullivan
authors.forename: Richard E
authors.initials: RE
authors.lastname: Buller
authors.forename: Joel I
authors.initials: JI
authors.lastname: Sorosky
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000097:blood / Q000627:therapeutic use*; D019540:Area Under Curve; D002277:Carcinoma / Q000097:blood / Q000188:drug therapy; D002851:Chromatography, High Pressure Liquid; D004247:DNA / Q000378:metabolism; D018450:Disease Progression; D005047:Etoposide / Q000008:administration & dosage* / Q000097:blood; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy*; D010534:Peritoneal Neoplasms / Q000097:blood / Q000188:drug therapy*; D012008:Recurrence; D013997:Time Factors; D019772:Topotecan / Q000008:administration & dosage* / Q000097:blood; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide; D019772:Topotecan; D004247:DNA